BI 1015550, Placebo matching nerandomilast (BI 1015550)
1305-0046
Phase 3 small_molecule active
Quick answer
BI 1015550, Placebo matching nerandomilast (BI 1015550) for Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active